UPPSALA SCIENCE PARK, Sweden, Jan. 28, 2002 (PRIMEZONE) -- Gyros AB announced the completion of purpose-built laboratories for production, application development and demonstrations. The new wing more than doubles the size of the Company's headquarters in Uppsala Science Park, Sweden
Expansion of facilities is an essential move to keep up with the rapid development of Gyros AB. There is a growing interest in the Company's unique technology platform from major pharmaceutical companies in Europe and the US and collaborations for custom-designed solutions are already under discussion.
"With centralized facilities we can ensure excellent communication from R&D through to manufacturing in order to facilitate a fast exchange of knowledge and so shorten the time to market for each new application of our CD microlaboratories. "said Per Sjoberg, Executive Vice President Commercial Operations. "Development and demonstration laboratories will help us to work closely with our clients as we miniaturize and integrate their applications and will allow them to test their samples on our systems."
"In-house manufacturing is the next key step in our commercialization process." explained Mr. Nils Kristensen, Vice President Operations, "Each CD microlaboratory is designed and optimized for a specific application before being produced in our in-house manufacturing plant. A well-developed CD production unit is essential for us to supply our industrial clients with the reliability and quality they demand from 'off-the-shelf' or customized products."
The technology platform from Gyros has the potential to miniaturize and integrate many different laboratory processes, but the Company will focus its first commercially available product towards the proteomics area in drug discovery. Product launch is anticipated early in 2002.
About Gyros AB
Gyros AB offers pharmaceutical, biotechnology and diagnostic companies a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into application- specific CDs. Hundreds of samples can be processed in parallel on these disposable microlaboratories. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures. The company was founded in 2000 as a spin-off from Amersham Biosciences and currently has more than 80 employees working at its headquarters in Uppsala Science Park, Sweden and in regional sales offices in the USA and UK.
Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.
This information was brought to you by Waymaker http://www.waymaker.net